Pure Bioscience Stock Fundamentals
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
Pure Bioscience fundamentals help investors to digest information that contributes to Pure Bioscience's financial success or failures. It also enables traders to predict the movement of Pure Pink Sheet. The fundamental analysis module provides a way to measure Pure Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pure Bioscience pink sheet.
Pure |
Pure Bioscience Company Return On Equity Analysis
Pure Bioscience's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pure Bioscience Return On Equity | -1.29 |
Most of Pure Bioscience's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pure Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Pure Bioscience has a Return On Equity of -1.2879. This is 148.78% lower than that of the Household Products sector and 108.77% lower than that of the Consumer Staples industry. The return on equity for all United States stocks is notably higher than that of the company.
Pure Bioscience Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pure Bioscience's current stock value. Our valuation model uses many indicators to compare Pure Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pure Bioscience competition to find correlations between indicators driving Pure Bioscience's intrinsic value. More Info.Pure Bioscience is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pure Bioscience's earnings, one of the primary drivers of an investment's value.Pure Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pure Bioscience's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pure Bioscience could also be used in its relative valuation, which is a method of valuing Pure Bioscience by comparing valuation metrics of similar companies.Pure Bioscience is currently under evaluation in return on equity category among its peers.
Pure Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 111.36 M | ||||
| Shares Owned By Insiders | 41.23 % | ||||
| Number Of Shares Shorted | 222.97 K | ||||
| Price To Earning | 12.49 X | ||||
| Price To Book | 3.85 X | ||||
| Price To Sales | 8.00 X | ||||
| Revenue | 1.85 M | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (3.27 M) | ||||
| Net Income | (3.49 M) | ||||
| Cash And Equivalents | 511 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 239 K | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 2.02 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (2.42 M) | ||||
| Short Ratio | 2.56 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 13.36 M | ||||
| Total Asset | 4.48 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Working Capital | 3.61 M | ||||
| Current Asset | 6.14 M | ||||
| Current Liabilities | 2.54 M | ||||
| Z Score | 0.8 | ||||
| Net Asset | 4.48 M |
About Pure Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pure Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pure Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pure Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |